No black box warning on record for Neo-Synalar

As of the latest FDA labeling reviewed, Neo-Synalar (NEOMYCIN SULFATE AND FLUOCINOLONE ACETONIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Neo-Synalar medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS If local infection should continue or become severe, or in the presence of systemic infection, appropriate systemic antibacterial therapy, based on susceptibility testing, should be considered. Because of the concern of nephrotoxicity and ototoxicity associated with neomycin, this combination product should not be used over a wide area or for extended periods of time. There are articles i

No black box warning on record for Neo-Synalar

Other warnings & precautions

WARNINGS If local infection should continue or become severe, or in the presence of systemic infection, appropriate systemic antibacterial therapy, based on susceptibility testing, should be considered. Because of the concern of nephrotoxicity and ototoxicity associated with neomycin, this combination product should not be used over a wide area or for extended periods of time. There are articles i

Neo-Synalar Black Box Warning

No black box warning on record for Neo-Synalar

Other warnings & precautions

Neo-Synalar Black Box Warning

No black box warning on record for Neo-Synalar

Other warnings & precautions